Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares rose 11.2% on Monday . The company traded as high as $12.50 and last traded at $12.43. Approximately 71,327 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 187,117 shares. The stock had previously closed at $11.18.
Analyst Ratings Changes
ZBIO has been the subject of several research analyst reports. Wedbush restated an "outperform" rating and set a $35.00 price target on shares of Zenas BioPharma in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Zenas BioPharma in a report on Friday, May 16th.
Get Our Latest Research Report on Zenas BioPharma
Zenas BioPharma Stock Performance
The stock's 50-day moving average is $10.18. The firm has a market capitalization of $536.26 million and a price-to-earnings ratio of -3.61.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $5.00 million.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at $348,000. Nuveen LLC purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at $250,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at $49,000.
About Zenas BioPharma
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
